Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence

• मुख्य लेखकों: Emir M. Muzurović MD, MM (लेखक), Špela Volčanšek MD (लेखक), Karin Zibar Tomšić MD, PhD (लेखक), Andrej Janež MD, PhD (लेखक), Dimitri P. Mikhailidis MD (लेखक), Manfredi Rizzo MD, PhD (लेखक), Christos S. Mantzoros MD (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: SAGE Publishing, 2022-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease (CVD). Lifestyle, as well as an imbala...